GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tibet Aim Pharm Inc (SZSE:002826) » Definitions » Gross Profit

Tibet Aim Pharm (SZSE:002826) Gross Profit : ¥362.1 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Tibet Aim Pharm Gross Profit?

Tibet Aim Pharm's gross profit for the three months ended in Mar. 2024 was ¥96.7 Mil. Tibet Aim Pharm's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was ¥362.1 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Tibet Aim Pharm's gross profit for the three months ended in Mar. 2024 was ¥96.7 Mil. Tibet Aim Pharm's Revenue for the three months ended in Mar. 2024 was ¥160.4 Mil. Therefore, Tibet Aim Pharm's Gross Margin % for the quarter that ended in Mar. 2024 was 60.25%.

Tibet Aim Pharm had a gross margin of 60.25% for the quarter that ended in Mar. 2024 => Durable competitive advantage

During the past 10 years, the highest Gross Margin % of Tibet Aim Pharm was 71.39%. The lowest was 31.94%. And the median was 51.42%.

Warning Sign:

Tibet Aim Pharm Inc gross margin has been in long-term decline. The average rate of decline per year is -5.5%.


Tibet Aim Pharm Gross Profit Historical Data

The historical data trend for Tibet Aim Pharm's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tibet Aim Pharm Gross Profit Chart

Tibet Aim Pharm Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 156.11 182.33 216.73 260.50 376.17

Tibet Aim Pharm Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 75.96 93.74 93.11 78.64 96.66

Competitive Comparison of Tibet Aim Pharm's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Tibet Aim Pharm's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tibet Aim Pharm's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tibet Aim Pharm's Gross Profit distribution charts can be found below:

* The bar in red indicates where Tibet Aim Pharm's Gross Profit falls into.



Tibet Aim Pharm Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Tibet Aim Pharm's Gross Profit for the fiscal year that ended in Dec. 2022 is calculated as

Gross Profit (A: Dec. 2022 )=Revenue - Cost of Goods Sold
=856.734 - 480.56
=376.2

Tibet Aim Pharm's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=160.426 - 63.769
=96.7

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥362.1 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Tibet Aim Pharm's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=96.7 / 160.426
=60.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Tibet Aim Pharm  (SZSE:002826) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Tibet Aim Pharm had a gross margin of 60.25% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Tibet Aim Pharm Gross Profit Related Terms

Thank you for viewing the detailed overview of Tibet Aim Pharm's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Tibet Aim Pharm (SZSE:002826) Business Description

Traded in Other Exchanges
N/A
Address
No. 6, Linqionggang Road, Lhasa Economic and Technological Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000
Tibet Aim Pharm Inc is the pharmaceutical company based in China. It is mainly engaged in the research and development, production and sales of chemical drugs and proprietary Chinese medicines for common chronic disease such as diabetes and cardiovascular disease as well as medicines for gynecology and obstetrics. The company's products offering includes miglitol tablets, gualoupi injection, nalmefene hydrochloride injection, carbetocin injection; hongjin xiaojie tablets and aceclofenac enteric-coated tablets. The company also expanded its products in the treatment of antibiotic, antiallergic and digestive system.
Executives
Peng Hui Director
Pang Guo Qiang Directors, executives
Li Qian Jin Securities Affairs Representative
Liu Hang Supervisors

Tibet Aim Pharm (SZSE:002826) Headlines

No Headlines